Data From Clinical Trials Identify Gaps In Health R&D05/06/2013 by Intellectual Property Watch Leave a CommentShare this Story:Click to share on Twitter (Opens in new window)Click to share on LinkedIn (Opens in new window)Click to share on Google+ (Opens in new window)Click to share on Facebook (Opens in new window)Click to email this to a friend (Opens in new window)Click to print (Opens in new window)Much of our best content is available only to IP Watch subscribers. We are a non-profit independent news service, and subscribing to our service helps support our goals of bringing more transparency to global IP and innovation policies. To access all of our content, please subscribe now.By Brittany Ngo for Intellectual Property WatchLower-income countries receive much less attention in terms of clinical trial research, according to a study published in this month’s World Health Organization (WHO) Bulletin. The study also underscored the value and importance the WHO International Clinical Trials Registry Platform (ICTRP) provides as a resource for evaluating the distribution of clinical trials around the world, and for providing information for future policy on health R&D. The study [pdf ] used clinical trial data to identify gaps in global health research and development (R&D). Authors of the study sought to analyse where and how clinical trials were being conducted, and for which diseases. They hoped to gain a clearer understanding of the “global landscape” of health R&D, using data from the ICTRP.The results showed a disproportionate amount of clinical trials dedicated to noncommunicable diseases (NCDs) in higher income countries.For every million disability-adjusted life years (DALYs) caused by communicable, maternal, perinatal and nutritional conditions; noncommunicable diseases; or injuries, the ICTRP database contained an estimated 7.4, 52.4 and 6.0 trials in which these causes of burden of disease were being investigated, respectively (out of a total 2,381 records of trials examined in the study).Regarding the distribution of trials based on wealth of countries, the study found that high-income countries had an estimated 292.7 registered trials compared with 13.4 in upper-middle-income, 3.0 in lower-middle-income, and 0.8 in low-income countries.Brittany Ngo is currently completing her Master’s in Health Policy and Global Health at the Yale School of Public Health and previously obtained a Bachelor’s of Arts in Economics from Georgetown University. Through her studies she has developed an interest in health-related intellectual property issues. She is a summer intern at Intellectual Property Watch.Share this Story:Click to share on Twitter (Opens in new window)Click to share on LinkedIn (Opens in new window)Click to share on Google+ (Opens in new window)Click to share on Facebook (Opens in new window)Click to email this to a friend (Opens in new window)Click to print (Opens in new window)Related"Data From Clinical Trials Identify Gaps In Health R&D" by Intellectual Property Watch is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.